Læknaneminn

Ataaseq assigiiaat ilaat

Læknaneminn - 01.04.1997, Qupperneq 126

Læknaneminn - 01.04.1997, Qupperneq 126
Peter Duesberg and David Rasnick demonstrates that the authors are clearly aware that a drug-free control group of HlV-positive AIDS patients is necessary to refute the drug hypothesis of AIDS, while at the same time supporting the orthodox view that HIV causes AIDS. However, the drug-free group reported by the authors proved to be an empty set, as no drug-free AIDS patients were recorded in the Nature commentary 11‘1’335. Our independent analysis of the data base also failed to identify the missing group of drug-free AIDS patients 115’221. Despite our chal- lenge in The Lancet 223, Genetica '15, and Science 3,6, to this date the authors have failed to come up with an explanation as to the origin of r/;«Vdrug-free group 337. 2) The re-investigation of the database of the Nature commentary further revealed that 45 drug-using, HIV- free patients had been omitted from the paper, although they had AIDS defining diseases "5. This brazen manipulation of the facts was legitimised with the CDC’s HIV antibody-based AIDS defmition 337 (see 2.). 3) The Nature commentary also omitted the fact that 73% of the HlV-positive AIDS patients were on AZT. However, in response to our challenge the authors acknowledged the AZT prescriptions 2 years later 303. Thus the drug hypothesis was refuted by claiming non-existing, drug-free AIDS patients, by hiding HIV- free AIDS patients, and by omitting widespread AZT use by AIDS patients. Numerous other epidemiologists have also investi- gated “HIV disease progression” 102 to AIDS in drug users 87,88,91‘93'101-104'106'279 without offering drug-free controls. Indeed, there is not a single epidemiological study in the bulging AIDS literature that ever described a group of HlV-positive people, without confounding health risks like drug use or hemophilia, progressing from HIV to AIDS n'225. This absence of drug-free controls is the single most damaging flaw of AIDS epidemiology. For example, Alcabes et al. conclude from a study of HlV-positive intravenous drug users from New York that, “The results of this analysis provide evidence for a mechanism by which the clinical factors that predict more rapid progression to AIDS, such as bacterial infection, might work, and why other factors, such as drug injection, are unrelated to AIDS rislc” 87. But no control is offered for drug-free AIDS. Based on analyses of HlV-positive intravenous drug users, “with 45% injecting at least once per day,” Margolick et al. conclude “that progression of HIV-1 infecdon in IV drug users, as reflected in the decline of CD4 cell counts, is no more rapid than that reported for other risk groups” 91. In an effort to exclude the role of drugs in AIDS, the authors pointed out that in a particular 6 month survey interval there was no “effect of active vs inactive drug use” on T cell loss. However, there was no verification for “inactive” drug use, and no informatiom as to whether “inactive” street drug use was substituted by methadone, which is itself immune suppressive 33S. Moreover there was no effort to determine the cumulative lifetime drug dose of active or “inactive” drug users that is essential to evalu- ate drug pathogenicity. There was also no information as to whether “other risk groups” included drug-free controls. It is also claimed that cohorts of HlV-positive male homosexuals using batteries of recreational drugs including, “alcohol, tobacco, cannabis, nitrites, cocaine and amphetamines” in addition to AZT developed AIDS from HIV infection alone without offering a population of drug-free HlV-patients as a control. For example, a “Tricontinental” study from San Francisco, Vancouver, Amsterdam and Sydney that was sponsored by the American NIAID concluded that, “None of the presented hazards is significant.” Although the study acknowledged that, “there were no appreciable differ- ences in the use of alcohol, tobacco or nitrites,” it insisted that, “Notably, nitrite use was not associated with disease progression, and the use of tobacco appears not to be related to progression to AIDS or P. carinii pneuntonia (data for the latter not shown)” 102. A remarkable “Tricontinental” conclusion! Likewise, the NIAID-sponsored MAC study of male homosexuals published that there is “No evidence for a role of alcohol or other psychoactive drugs in accelerat- ing immunodeficiency in HIV-1 positive individuals” 103 although it had never identified even one drug-free, HlV-positive homosexual with AIDS in 10 years 109. Indeed, a recent report from the MAC study, published in the Journal of Substance Abuse seems to contradict their earlier message: “Men who combined volatile nitrite (popper) use with other recreational drugs were at highest risk both behaviorally and in terms of human immunodeficiency virus-1 (HIV) seroconver- sion throughout the study.” All of the 500-800 homo- LÆKNANEMINN 124 1 ■ tbl. 1997, 50. árg.
Qupperneq 1
Qupperneq 2
Qupperneq 3
Qupperneq 4
Qupperneq 5
Qupperneq 6
Qupperneq 7
Qupperneq 8
Qupperneq 9
Qupperneq 10
Qupperneq 11
Qupperneq 12
Qupperneq 13
Qupperneq 14
Qupperneq 15
Qupperneq 16
Qupperneq 17
Qupperneq 18
Qupperneq 19
Qupperneq 20
Qupperneq 21
Qupperneq 22
Qupperneq 23
Qupperneq 24
Qupperneq 25
Qupperneq 26
Qupperneq 27
Qupperneq 28
Qupperneq 29
Qupperneq 30
Qupperneq 31
Qupperneq 32
Qupperneq 33
Qupperneq 34
Qupperneq 35
Qupperneq 36
Qupperneq 37
Qupperneq 38
Qupperneq 39
Qupperneq 40
Qupperneq 41
Qupperneq 42
Qupperneq 43
Qupperneq 44
Qupperneq 45
Qupperneq 46
Qupperneq 47
Qupperneq 48
Qupperneq 49
Qupperneq 50
Qupperneq 51
Qupperneq 52
Qupperneq 53
Qupperneq 54
Qupperneq 55
Qupperneq 56
Qupperneq 57
Qupperneq 58
Qupperneq 59
Qupperneq 60
Qupperneq 61
Qupperneq 62
Qupperneq 63
Qupperneq 64
Qupperneq 65
Qupperneq 66
Qupperneq 67
Qupperneq 68
Qupperneq 69
Qupperneq 70
Qupperneq 71
Qupperneq 72
Qupperneq 73
Qupperneq 74
Qupperneq 75
Qupperneq 76
Qupperneq 77
Qupperneq 78
Qupperneq 79
Qupperneq 80
Qupperneq 81
Qupperneq 82
Qupperneq 83
Qupperneq 84
Qupperneq 85
Qupperneq 86
Qupperneq 87
Qupperneq 88
Qupperneq 89
Qupperneq 90
Qupperneq 91
Qupperneq 92
Qupperneq 93
Qupperneq 94
Qupperneq 95
Qupperneq 96
Qupperneq 97
Qupperneq 98
Qupperneq 99
Qupperneq 100
Qupperneq 101
Qupperneq 102
Qupperneq 103
Qupperneq 104
Qupperneq 105
Qupperneq 106
Qupperneq 107
Qupperneq 108
Qupperneq 109
Qupperneq 110
Qupperneq 111
Qupperneq 112
Qupperneq 113
Qupperneq 114
Qupperneq 115
Qupperneq 116
Qupperneq 117
Qupperneq 118
Qupperneq 119
Qupperneq 120
Qupperneq 121
Qupperneq 122
Qupperneq 123
Qupperneq 124
Qupperneq 125
Qupperneq 126
Qupperneq 127
Qupperneq 128
Qupperneq 129
Qupperneq 130
Qupperneq 131
Qupperneq 132
Qupperneq 133
Qupperneq 134
Qupperneq 135
Qupperneq 136
Qupperneq 137
Qupperneq 138
Qupperneq 139
Qupperneq 140

x

Læknaneminn

Direct Links

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknaneminn
https://timarit.is/publication/1885

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.